We define adjusted net profit (non-IFRS measure) as profit for the year from continuing operations adjusted for share-based payment expenses, which are non-cash in nature.
The use of such non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for an analysis of, our results of operations or financial condition as reported under IFRS.
We define adjusted net (loss)/profit (Non-IFRS Measure) as (loss)/profit for the year excluding equity-settled share-based payment expenses, changes in the carrying amount of redemption liabilities and [REDACTED] expense.
Share-based payment expenses represent the fair value of the shares granted at the date of grant taking into account the consideration for subscription of the equity interests.
Summary · 第 10 页
The item is adjusted as it is non-cash, and is not expected to result in our future cash payments.
The amount of the share-based payment represented the difference between the fair value of acquired equity interests and the consideration paid.
Summary · 第 9 页
In addition, the net loss was also attributable to share-based payments of RMB9.8 million and [REDACTED] expenses of RMB[REDACTED] million incurred during the year.
We define adjusted net profit (Non-IFRS measure) for the year/period as profit for the year/period adjusted by adding back (i) equity-settled share-based payment expenses, which are non-cash in nature, (ii) interest expenses for redemption right, which will be converted into equity of the Company upon the Listing, and (iii) listing expense, which are related to the Global Offering.
Summary · 第 11 页
(ii) share-based payment expenses remained and will remain an ongoing expense from 2025 to 2029, as we provide long-term incentive programs to employees to motivate and retain talent; and
We have a share incentive plan adopted in 2021 (the “Share Incentive Scheme of the Company”), under which we receive services from employees as consideration for restricted shares of our Company.
Financial Information · 第 175 页
The fair value of the equity-settled share-based payments determined at the grant date without taking into consideration all non-market vesting conditions is expensed using graded vesting method over the vesting period, based on the our estimate of equity instruments that will eventually vest, with a corresponding increase in equity (share-based payments reserve).
Share-based payments which are both equity-settled and cash-settled in nature, and related to our restricted A share incentive schemes for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group’s operations.
We define adjusted loss for the year/period (non-IFRS measure) as loss for the year/period adjusted by adding back (i) changes in the carrying amount of redemption liabilities, representing the carrying amounts changes of the redemption rights granted by us, which is non-cash in nature and will be reclassified to equity after the termination of the investors’ redemption rights upon Listing, (ii) equity settled share-based payment, which was non-cash in nature and represented the employee benefit expenses incurred in connection with our award to management and key employees, and (iii) Listing expenses, which represented expenses in relation to the Global Offering.
Summary · 第 8 页
Our net loss for the year ended December 31, 2025 is expected to increase compared to 2024, mainly attributable to (i) one-off listing expenses and (ii) increased employee compensation expenses including equity settled share-based payments.
We have granted share options to our employees during the Track Record Period, which was later converted into RSU Scheme.
Financial Information · 第 330 页
Specifically, the fair value loss of convertible redeemable preference shares and share-based compensation expenses in aggregate amounted to RMB98.5 million and RMB298.6 million in 2022 and 2023, respectively.
Share-based payment expenses are non-cash in nature and represent the arrangement under which we received services from employees as consideration for our equity instruments.
Summary · 第 14 页
We define adjusted net profit (non-IFRS measures) as profit for the year/period adjusted by adding back share-based payment expenses and listing expenses.
The fair value is determined by an external valuer based on a recent transaction price, further details of which are given in Note 32 to the Accountants' Report as set out in Appendix I to this prospectus.
Financial Information · 第 311 页
The cost of equity-settled transactions is recognised in employee benefit expense, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled.
Share based payment expenses mainly represent the non-cash employee benefit expenses incurred in connection with our award to management and key employees.
Summary · 第 8 页
We expect a significant increase in net loss in 2025, primarily due to the increase in share-based payments, investments in research and development and the Listing expenses.
北京智谱华章科技股份有限公司Knowledge Atlas Technology Joint Stock Company Limited02513.HK
股份支付费用及2025年预期大增
Equity-settled share-based compensation expenses represented share-based compensation expenses incurred in connection with our share incentive plan. Equity-settled share-based compensation expenses are not expected to result in future cash payments. The reconciling item is non-cash and does not result in cash outflow, and the adjustment has been consistently made during the Track Record Period.
Summary · 第 15 页
Except for an expected temporary increase in our general and administration expense as a percentage of our revenue in 2025 primarily due to expected significant increase in equity-settled sharebased compensation expenses and expected listing expenses, we expect our general and administration expenses to remain relatively stable as percentage of our revenue in the near future with a decrease in such percentage in the long run.
We operate certain share incentive plans, under which it receives services from employees as consideration for equity instruments (including share options and restricted shares) of the Company.
Financial Information · 第 357 页
Specifically, (i) changes in the carrying value of redemption liabilities are non-cash in nature, because the redemption right of the shareholders shall automatically terminate immediately upon the completion of the Listing, (ii) share-based compensation expenses relates to the share-based awards that we grant to employees and Directors and is a non-cash expense, and (iii) listing expenses relates to this Global Offering.
英矽智能INSILICO MEDICINE InSilico Medicine Cayman TopCo03696.HK
股份支付开支往绩期间合计约2,850万美元
Our share-based compensation expenses represent expenses associated with equity compensation to retain and reward persons performing services to us, which are non-cash in nature.
Summary · 第 17 页
Our Company expects an increased net loss in 2025, primarily due to continued investment in growth initiatives, including elevated research and development activities, costs associated with the ongoing listing process, and ongoing share-based compensation.
Our net loss in 2024 was also attributable to the substantial increase in equity-settled share-based payment expenses, which reflects one-off share-based payments.
Share-based compensation relates to the share options that we have granted under our share incentive plan, which is a non-cash expense.
Summary · 第 12 页
We have used binomial option-pricing model to determine the total fair value of the options granted to employees, which is to be expensed over the vesting period.